1-844-762-9522 info@rdxbioscience.com

Genetics

Pharmacogenomics Panels

ReasonAlgos, PGx for Pain Medicine

CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5,CYP1A2, CYP2B6, OPRM2, COMTJ

ReasonMed, PGx for Primary Medicine

CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, NAT1 NAT2, VKORC1

ReasonCor, PGx for Cardiology

CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5,  VKORC1, MTHFR, APO E, SLCO1B1, F II, FV

ReasonMH, PGx in Psychiatry

CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP1A2, COMT, ANKK/DRD2, MTHFR

Comprehensive

 CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, COMT, CYP3A4, CYP3A5, ANKK/DRD2, MTHFR, OPRM1, VKORC1, SLC01B1, F II,

Hereditary Cancer Screening

Comprehensive

APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4**, CHEK2, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53, EPCAM**, MITF**, BAP1, CDKN2A, GREM1**, POLD1**POLE**, PMS2**

Uterine

MLH1, MSH2, MSH6, PMS2***, EPCAM**, TP53, PTEN, STK11

Ovarian Panel

BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2***, EPCAM**, TP53, STK11, PALB2, BARD1, BRIP1, RAD51C, RAD51D

Breast Panel

BRCA1, BRCA2, TP53, PTEN, STK11, CDH1, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1

Colorectal

MLH1, MSH2, MSH6, PMS2***, EPCAM**, APC, MUTYH, TP53, STK11, BMPR1A, SMAD4, GREM1**, POLD1**, POLE**, CHEK2, PTEN

Pancreatic

BRCA1, BRCA2, MLH1, MSH2, EPCAM**, APC, CDKN2A, TP53, STK11, BMPR1A, SMAD4, PALB2, ATM

*Please note that research and screening guidelines for genes associated with hereditary prostate cancer are still in their early stages. It is part of the color service to keep you updated if any information related to your results changes.

** Only positions known to impact cancer risk analyzed: CDK4: only chr12:g.58145429_58145431 (codon 24) analyzed, EPCAM: only large deletions and duplications including 3’ end of the gene analyzed, GREM 1: only duplications in the upstream region analyzed, MITF: only chr3:g.70014091 ( including c:952G>A) analyzed, POLD1: only chr19:g.50909713 (including c.1433G>A) analyzed, POLE: only chr12:g.133250250 (including c.1270C>G) analyzed.

*** PMS@: Exons 12-15 not analyzed.

RDx BioScience embraces and supports ASAM guidelines for appropriate testing:

Z

Clinical leadership of addictionology physicians with decades of expertise

Z

Ongoing validation for testing of newly designed synthetic drugs

Z

Guidance on best practices for diagnostics in addiction treatment

Z

Very low testing cutoff levels

Z

Rapid turnaround times necessary for appropriate treatment

Z

Consultations with PhD toxicologists for rapid interpretation of results

Z

A full blood and genetics test menu, to evaluate the complete health of the client who seeks sobriety

Z

Oral testing capabilities

Share This